Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism

A randomized, double blind, placebo-controlled trial

Paolo Moghetti, Flavia Tosi, Antonella Tosti, Carlo Negri, Cosimo Misciali, Fabrizia Perrone, Marco Caputo, Michele Muggeo, Roberto Castello

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with i of these 3 drugs or placebo for 6 months. Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. These measurements were averaged to produce a mean hair shaft diameter. For each subject, baseline and posttreatment assessments were carried out at the same time by an investigator blinded to both time and type of therapy. In addition, a semi-quantitative clinical evaluation was carried out by a modification of the Ferriman-Gallwey (F-G) scoring method, performed by a single investigator. At baseline the 4 groups of women had similar hair diameters and F-G scores. After 6 months of therapy all groups of subjects given active drugs showed reductions of their hair diameters, without statistically significant differences among groups (mean change ± SEM, -11.7 ± 5.6%, -18.0 ± 6.1%, and -12.6 ± 6.7%, respectively, in the spironolactone, flutamide, and finasteride groups). F-G scores were also significantly reduced in women receiving antiandrogen drugs, again without differences among groups (mean change, -41.0 ± 5.5%, -38.9 ± 7.2%, and -31.6 ± 3.7%, respectively). No significant changes from baseline values were recorded by either hair diameter (-1.4 ± 5.2%) or F-G score (+5.4 ± 3.7%) assessment in the placebo group. In conclusion, spironolactone, flutamide, and finasteride are all effective in the treatment of hirsutism. After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume85
Issue number1
DOIs
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Finasteride
Flutamide
Hirsutism
Spironolactone
Hair
Placebos
Pharmaceutical Preparations
Androgen Antagonists
Therapeutics
Research Personnel
Optical microscopy
Group Psychotherapy
Scanning electron microscopy
Microscopy
Research Design
Light

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism : A randomized, double blind, placebo-controlled trial. / Moghetti, Paolo; Tosi, Flavia; Tosti, Antonella; Negri, Carlo; Misciali, Cosimo; Perrone, Fabrizia; Caputo, Marco; Muggeo, Michele; Castello, Roberto.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 1, 01.12.2000, p. 89-94.

Research output: Contribution to journalArticle

Moghetti, Paolo ; Tosi, Flavia ; Tosti, Antonella ; Negri, Carlo ; Misciali, Cosimo ; Perrone, Fabrizia ; Caputo, Marco ; Muggeo, Michele ; Castello, Roberto. / Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism : A randomized, double blind, placebo-controlled trial. In: Journal of Clinical Endocrinology and Metabolism. 2000 ; Vol. 85, No. 1. pp. 89-94.
@article{6fdda920e5d44b28834fa6e8facabf7c,
title = "Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial",
abstract = "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with i of these 3 drugs or placebo for 6 months. Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. These measurements were averaged to produce a mean hair shaft diameter. For each subject, baseline and posttreatment assessments were carried out at the same time by an investigator blinded to both time and type of therapy. In addition, a semi-quantitative clinical evaluation was carried out by a modification of the Ferriman-Gallwey (F-G) scoring method, performed by a single investigator. At baseline the 4 groups of women had similar hair diameters and F-G scores. After 6 months of therapy all groups of subjects given active drugs showed reductions of their hair diameters, without statistically significant differences among groups (mean change ± SEM, -11.7 ± 5.6{\%}, -18.0 ± 6.1{\%}, and -12.6 ± 6.7{\%}, respectively, in the spironolactone, flutamide, and finasteride groups). F-G scores were also significantly reduced in women receiving antiandrogen drugs, again without differences among groups (mean change, -41.0 ± 5.5{\%}, -38.9 ± 7.2{\%}, and -31.6 ± 3.7{\%}, respectively). No significant changes from baseline values were recorded by either hair diameter (-1.4 ± 5.2{\%}) or F-G score (+5.4 ± 3.7{\%}) assessment in the placebo group. In conclusion, spironolactone, flutamide, and finasteride are all effective in the treatment of hirsutism. After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar.",
author = "Paolo Moghetti and Flavia Tosi and Antonella Tosti and Carlo Negri and Cosimo Misciali and Fabrizia Perrone and Marco Caputo and Michele Muggeo and Roberto Castello",
year = "2000",
month = "12",
day = "1",
doi = "10.1210/jc.85.1.89",
language = "English",
volume = "85",
pages = "89--94",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism

T2 - A randomized, double blind, placebo-controlled trial

AU - Moghetti, Paolo

AU - Tosi, Flavia

AU - Tosti, Antonella

AU - Negri, Carlo

AU - Misciali, Cosimo

AU - Perrone, Fabrizia

AU - Caputo, Marco

AU - Muggeo, Michele

AU - Castello, Roberto

PY - 2000/12/1

Y1 - 2000/12/1

N2 - To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with i of these 3 drugs or placebo for 6 months. Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. These measurements were averaged to produce a mean hair shaft diameter. For each subject, baseline and posttreatment assessments were carried out at the same time by an investigator blinded to both time and type of therapy. In addition, a semi-quantitative clinical evaluation was carried out by a modification of the Ferriman-Gallwey (F-G) scoring method, performed by a single investigator. At baseline the 4 groups of women had similar hair diameters and F-G scores. After 6 months of therapy all groups of subjects given active drugs showed reductions of their hair diameters, without statistically significant differences among groups (mean change ± SEM, -11.7 ± 5.6%, -18.0 ± 6.1%, and -12.6 ± 6.7%, respectively, in the spironolactone, flutamide, and finasteride groups). F-G scores were also significantly reduced in women receiving antiandrogen drugs, again without differences among groups (mean change, -41.0 ± 5.5%, -38.9 ± 7.2%, and -31.6 ± 3.7%, respectively). No significant changes from baseline values were recorded by either hair diameter (-1.4 ± 5.2%) or F-G score (+5.4 ± 3.7%) assessment in the placebo group. In conclusion, spironolactone, flutamide, and finasteride are all effective in the treatment of hirsutism. After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar.

AB - To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with i of these 3 drugs or placebo for 6 months. Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. These measurements were averaged to produce a mean hair shaft diameter. For each subject, baseline and posttreatment assessments were carried out at the same time by an investigator blinded to both time and type of therapy. In addition, a semi-quantitative clinical evaluation was carried out by a modification of the Ferriman-Gallwey (F-G) scoring method, performed by a single investigator. At baseline the 4 groups of women had similar hair diameters and F-G scores. After 6 months of therapy all groups of subjects given active drugs showed reductions of their hair diameters, without statistically significant differences among groups (mean change ± SEM, -11.7 ± 5.6%, -18.0 ± 6.1%, and -12.6 ± 6.7%, respectively, in the spironolactone, flutamide, and finasteride groups). F-G scores were also significantly reduced in women receiving antiandrogen drugs, again without differences among groups (mean change, -41.0 ± 5.5%, -38.9 ± 7.2%, and -31.6 ± 3.7%, respectively). No significant changes from baseline values were recorded by either hair diameter (-1.4 ± 5.2%) or F-G score (+5.4 ± 3.7%) assessment in the placebo group. In conclusion, spironolactone, flutamide, and finasteride are all effective in the treatment of hirsutism. After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar.

UR - http://www.scopus.com/inward/record.url?scp=0034457586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034457586&partnerID=8YFLogxK

U2 - 10.1210/jc.85.1.89

DO - 10.1210/jc.85.1.89

M3 - Article

VL - 85

SP - 89

EP - 94

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -